Combination therapy for non-small cell lung cancer studied in new clinical trial
Non-small cell lung cancer (NSCLC), the most common type of lung cancer, is slow growing and can affect smokers and non-smokers alike. David S. Schrump, M.D., Surgical Chief of the Thoracic and Gastrointestinal Oncology Branch, is leading the NCI’s participation in a multicenter trial of nivolumab with or without tetrahydrouridine-decitabine (THU-Dec) in patients with NSCLC. Nivolumab is a cancer drug that blocks the action of certain proteins that stop the immune system from attacking tumor cells. THU-Dec is composed of decitabine, a cancer drug that attacks abnormal cells in the body, and tetrahydrouridine, which helps decitabine work better. The aim of this study is to see if THU-Dec can boost the immune system’s response to nivolumab and improve outcomes for patients with NSCLC.
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow by treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland. Search all CCR clinical trials, and subscribe to have the latest CCR clinical trials sent to your inbox.Summary Posted: Mon, 01/01/2018